VolitionRx (NYSE-A:VNRX) said it is hosting a roundtable discussion in Athens this weekend which will bring together world-renowned experts in sepsis, a life-threatening condition that occurs in response to an infection.
The company said the roundtable, chaired by Professor of Medicine at University Paris Saclay-UVSQ Djillali Annane, will cover the challenges of sepsis, the link between Neutrophil Extracellular Traps (NETs) and sepsis, and how Volition's Nu.Q NETs technology could potentially be used effectively in clinical practice.
The event is being hosted by Evangelos J. Giamarellos-Bourboulis, Professor of Internal Medicine at The National and Kapodistrian University of Athens in Greece and Chairman of the European Sepsis Alliance.
It is taking place during Sepsis Awareness Month and coincides with World Sepsis Day, a global initiative aimed at raising awareness of the disease which accounts for at least 11 million deaths globally.
"We are delighted to bring together some of the world's most distinguished experts in the field of sepsis, spanning a wide range of specialisms including intensive care medicine, pediatric sepsis, immunology, ctDNA, hematology, and critical care medicine,” Professor Annane said in a statement.
"Together, we will discuss the challenges we face in detecting and treating sepsis, and the role of NETs. We will share research around potential treatments, examine different approaches to personalizing care, and consider how best to introduce pioneering diagnostic tools, like Volition's Nu.Q NETs test, into clinical practice."
Volition’s Nu.Q NETs test is a simple, low cost and routine blood test which can detect clinically elevated levels of NETs by identifying the unique biomarker H3.1, the company’s Medical Consultant Dr. Andrew Retter explained.
“Composed of decondensed chromatin, NETs play an important role in our immune system with a unique ability to counter infections by trapping and killing bacterial and viral particles,” Dr. Retter said.
“However, abnormal levels have been linked to a range of life-threatening conditions including severe sepsis, where they can provide valuable prognostic information.”
Volition noted that its Nu.Q NETs test is CE-marked, meaning it can be used for clinical purposes across Europe.
The company said it continues to liaise with the United States Food and Drug Administration (FDA) regarding its U.S. clinical and regulatory program.
VolitionRx (NYSE-A:VNRX) is a multi-national epigenetics company powered by Nu.Q, its proprietary nucleosome quantification platform.
Through its subsidiaries, Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie